Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

Long-term Immune, Neurobiological, and Gut-vaginal-urinary axis Exhaustion post-UTI: Research and Rehabilitation

Objectif

Urinary tract infections (UTIs) affected an estimated 404.6 million people globally in 2019, contributing to nearly 236,786 deaths and 5.2 million Disability-Adjusted Life Years. For a substantial subset of patients (approximately 25–70% of women), a first UTI is not an isolated event but the beginning of a self-reinforcing cycle of recurrence, repeated antibiotic exposure, microbiome disruption, and epithelial vulnerability. The LINGER project (Long-term Immune, Neurobiological, and Gut–vaginal–urinary axis Exhaustion post-UTI: Research and Rehabilitation) aims to provide the first comprehensive molecular characterisation of this post-infection recurrence state and to deliver diagnostic tools, validated interventions, and structured rehabilitation strategies to transform its management.

LINGER is structured around three objectives. (1) Map & Stratify: establish a pan-European cohort of pre-menopausal women (18–50 years) across Germany, the Netherlands, and Italy, and apply integrated multi-omics (targeted genome sequencing, metagenomics, metatranscriptomics, proteomics/peptidomics, epigenomics, and metabolic modelling) and AI-driven analysis to develop the Virtual Urinary-Tract Twin, a predictive model of post-infection recurrence risk. (2) Dissect & Validate: use in vitro (3D urothelial models) and in vivo (mouse rUTI models) systems to identify and validate causal mechanisms. (3) Intervene & Empower: translate findings into a precision Bacterial-Like Particle (BLiP) mucosal immunotherapy, pilot a digital-first patient self-management and education platform (Post-UTI Recovery Programme), and conduct a comprehensive burden-of-illness assessment to support healthcare integration.

By delivering a predictive diagnostic tool, a Phase 1-ready immunotherapy candidate, and an evidence-based digital care platform, LINGER will shift rUTI management from reactive antibiotic use to proactive, precision prevention, advancing innovations from TRL 2–3 to TRL 4–5.

Champ scientifique (EuroSciVoc)

Mots‑clés

Programme(s)

Thème(s)

Régime de financement

HORIZON-RIA - HORIZON Research and Innovation Actions

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) HORIZON-HLTH-2026-01

Voir tous les projets financés au titre de cet appel

Coordinateur

JUSTUS-LIEBIG-UNIVERSITAET GIESSEN
Contribution nette de l'UE
€ 1 084 372,50
Coût total
Aucune donnée

Participants (13)